Zenith Drugs P/E Ratio
Current P/E Ratio
7.69
Low Valuation
Very Low - Potentially undervalued or facing challenges
Zenith Drugs (ZENITHDRUG) P/E ratio is 7.69 (Low), EPS (TTM) ₹5.63, current price ₹ on None — Very Low - Potentially undervalued or facing challenges. Compare with Zenith Drugs valuation methods to assess whether the stock is under or overvalued.
Current Valuation Metrics
P/E Ratio
7.69
Current Price
₹
EPS (TTM)
₹5.63
Exchange
None
Valuation Signal
Signal
Undervalued
Sector Context
Sector Average
54.87
Sector Median
30.62
Sector Rank
#11 of 197
Sector Percentile
5.6%
ZENITHDRUG P/E Ratio — Valuation Signal & Historical Context
Zenith Drugs P/E 7.69 — signal: Undervalued. View ZENITHDRUG 52-week high low for the annual high/low range and current price position.
- Stock appears undervalued with PE of 7.69, suggesting potential buying opportunity
- Trading at discount to sector average PE of 54.87
ZENITHDRUG vs Healthcare Peers — P/E Ratio Comparison
Zenith Drugs P/E 7.69 vs Healthcare average 54.87, median 30.62 — range 2.86–706.0.
Sector Average
54.87
Sector Median
30.62
Lowest P/E
2.86
Highest P/E
706.0
Companies
197
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.29 | ₹53 | Low |
| Colinz Laboratories | COLINZ | 3.6 | ₹10 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.05 | ₹6,404 | Low |
| Sunrest Lifescience | SUNREST | 4.19 | ₹67 | Low |
| Shelter Pharma | SHELTER | 4.99 | ₹46 | Low |
| JFL Life Sciences | JFLLIFE | 5.83 | ₹78 | Low |
| GKB Ophthalmics | GKB | 5.94 | ₹33 | Low |
| Dipna Pharmachem | DPL | 6.52 | ₹18 | Low |
| Royal Sense | ROYAL | 6.73 | ₹48 | Low |